NASDAQ:TLSA - Tiziana Life Sciences Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $9.50
  • Forecasted Upside: 292.56 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$2.42
▼ -0.11 (-4.35%)
1 month | 3 months | 12 months
Get New Tiziana Life Sciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TLSA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TLSA

Average Price Target: $9.50
▲ +292.56% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Tiziana Life Sciences in the last 3 months. The average price target is $9.50, with a high forecast of $11.00 and a low forecast of $8.00. The average price target represents a 292.56% upside from the last price of $2.42.

Buy

The current consensus among 2 contributing investment analysts is to buy stock in Tiziana Life Sciences. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/29/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/28/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/26/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/24/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/23/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/23/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/22/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/21/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/22/2020B. RileyInitiated CoverageBuy$8.00High
9/21/2020HC WainwrightReiterated RatingBuy$25.00 ➝ $11.00High
7/17/2020HC WainwrightReiterated RatingBuy$25.00High
7/6/2020HC WainwrightReiterated RatingBuy$25.00Medium
6/5/2020HC WainwrightReiterated RatingBuy$25.00Medium
5/29/2020HC WainwrightReiterated RatingBuy$25.00Low
9/10/2019LaidlawSet Price TargetBuy$20.00N/A
12/17/2018LaidlawInitiated CoverageBuy ➝ BuyHigh
12/14/2018HC WainwrightReiterated RatingBuyMedium
(Data available from 6/21/2016 forward)
Tiziana Life Sciences logo
Tiziana Life Sciences Plc, a clinical stage biotechnology company, focuses on the discovery and development of molecules and related diagnostics to treat diseases in oncology and immunology in the United Kingdom. The company's product pipeline includes Foralumab (TZLS-401), a human anti-CD3 monclonal antibody for the treatment of autoimmune and inflammatory diseases, such as GvHD, ulcerative colitis, Crohn's disease, multiple sclerosis, type-1 diabetes, inflammatory bowel diseases, psoriasis, and rheumatoid arthritis; and Milciclib (TZLS-201), which is an orally bioavailable, small molecule inhibitor of cyclin-dependent kinases and Src family kinases for the treatment of hepatocellular carcinoma. It also develops anti-IL6R (TZLS-501), a human anti-interleukin-6 receptor monoclonal antibody for the treatment of IL6-induced inflammation, primarily to treat COVID-19 patients with severe respiratory symptoms. The company was founded in 2013 and is headquartered in London, the United Kingdom. Tiziana Life Sciences Plc is a subsidiary of Planwise Group Limited.
Read More

Today's Range

Now: $2.42
Low: $2.42
High: $2.59

50 Day Range

MA: $2.44
Low: $2.10
High: $3.15

52 Week Range

Now: $2.42
Low: $1.76
High: $12.17

Volume

1,000,800 shs

Average Volume

773,333 shs

Market Capitalization

$155.41 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.03

Frequently Asked Questions

What sell-side analysts currently cover shares of Tiziana Life Sciences?

The following Wall Street research analysts have issued research reports on Tiziana Life Sciences in the last twelve months: B. Riley, HC Wainwright, and Zacks Investment Research.
View the latest analyst ratings for TLSA.

What is the current price target for Tiziana Life Sciences?

2 Wall Street analysts have set twelve-month price targets for Tiziana Life Sciences in the last year. Their average twelve-month price target is $9.50, suggesting a possible upside of 292.6%. HC Wainwright has the highest price target set, predicting TLSA will reach $11.00 in the next twelve months. B. Riley has the lowest price target set, forecasting a price of $8.00 for Tiziana Life Sciences in the next year.
View the latest price targets for TLSA.

What is the current consensus analyst rating for Tiziana Life Sciences?

Tiziana Life Sciences currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe TLSA will outperform the market and that investors should add to their positions of Tiziana Life Sciences.
View the latest ratings for TLSA.

What other companies compete with Tiziana Life Sciences?

How do I contact Tiziana Life Sciences' investor relations team?

Tiziana Life Sciences' physical mailing address is 3RD FLOOR 11-12 ST. JAMES`S SQUARE, LONDON X0, SW1Y 4LB. The company's listed phone number is 442074952379 and its investor relations email address is [email protected] The official website for Tiziana Life Sciences is www.tizianalifesciences.com.